N-Carbobenzyloxy-N',N'-bis-(t-Butoxycarbonylmethyl)-ethylenediamine | 207612-89-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Carbobenzyloxy-N',N'-bis-(t-Butoxycarbonylmethyl)-ethylenediamine
• 英文别名: Tert-butyl 2-[[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-[2-(phenylmethoxycarbonylamino)ethyl]amino]acetate
• CAS: 207612-89-3
• 化学式: C₂₂H₃₄N₂O₆
• 分子量: 422.522
• InChiKey: XXQQPDQKSHGUMW-UHFFFAOYSA-N

物化性质

• 沸点：
  522.5±50.0 °C(Predicted)
• 密度：
  1.112±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  30
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  94.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-Carbobenzyloxy-N',N'-bis-(t-Butoxycarbonylmethyl)-ethylenediamine 在 palladium on activated charcoal 氢气 作用下， 以 二氯甲烷 为溶剂， 生成 (Z)-3-[2-(Bis-tert-butoxycarbonylmethyl-amino)-ethylcarbamoyl]-acrylic acid
  参考文献：
  名称：

  Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages

  摘要：

  Bivalent doxorubicin (DOX)-dipeptides (16a-c) were prepared and conjugated to the monoclonal antibody BR96. The dipeptides are cleaved by lysosomal proteases following internalization of the resulting immunoconjugates. Conjugate 18b demonstrated antigen-specific in vitro tumor cell killing activity (IC50 = 0.2 muM) that was equipotent to DOX with a near doubling of drug molecules/MAb. Size exclusion chromatography showed 18b to be a noncovalent dimer that was formed immediately upon conjugation. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00194-4
• 作为产物：
  描述：

  1,2-Ethanediylbis(phenylmethyl carbamate) 在 盐酸 、 potassium hydrogencarbonate 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-Carbobenzyloxy-N',N'-bis-(t-Butoxycarbonylmethyl)-ethylenediamine
  参考文献：
  名称：

  Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages

  摘要：

  Bivalent doxorubicin (DOX)-dipeptides (16a-c) were prepared and conjugated to the monoclonal antibody BR96. The dipeptides are cleaved by lysosomal proteases following internalization of the resulting immunoconjugates. Conjugate 18b demonstrated antigen-specific in vitro tumor cell killing activity (IC50 = 0.2 muM) that was equipotent to DOX with a near doubling of drug molecules/MAb. Size exclusion chromatography showed 18b to be a noncovalent dimer that was formed immediately upon conjugation. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00194-4

文献信息

• Facile synthesis of maleimide bifunctional linkers
  作者：H.Dalton King、Gene M Dubowchik、Michael A Walker

  DOI：10.1016/s0040-4039(02)00192-2

  日期：2002.3

  The synthesis of maleimide containing derivatives capable of serving as linkers for the conjugation of proteins is described. These compounds differ from previously reported linkers by having multiple sites available for drug attachment. Compounds 3a, 3b, and 3d were synthesized from the corresponding amino alcohols by the addition of two equivalents of t-butyl bromoacetate to a series of amino alcohols

  描述了含有马来酰亚胺的衍生物的合成，该衍生物能够用作蛋白质缀合的连接体。这些化合物与先前报道的接头不同，其具有多个可用于药物附着的位点。通过将两当量的溴乙酸叔丁酯添加到一系列氨基醇中，然后在Mitsunobu反应条件下引入马来酰亚胺并进行酯水解，由相应的氨基醇合成化合物3a，3b和3d。
• Branched peptide linkers
  申请人：Bristol-Myers Squibb Company

  公开号：US06759509B1

  公开（公告）日：2004-07-06

  Conjugates containing a targeting ligand, such as an antibody, a therapeutically active drug and a branched peptide linker. The branched peptide linker contains two or more amino acid moieties that provide an enzyme cleavage site. The number of drugs capable of being bonded to the branched linkers varies by a factor of two for each generation of branching.

  含有靶向配体（如抗体）、治疗活性药物和支链肽连接物的共轭物。支链肽连接物包含两个或更多氨基酸基团，提供酶切位点。每一代分支，可结合到支链连接物的药物数量会增加两倍。
• US6759509B1
  申请人：——

  公开号：US6759509B1

  公开（公告）日：2004-07-06
• Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages
  作者：Gene M Dubowchik、Shilpa Radia、Harold Mastalerz、Michael A Walker、Raymond A Firestone、H Dalton King、Sandra J Hofstead、David Willner、Shirley J Lasch、Pamela A Trail

  DOI：10.1016/s0960-894x(02)00194-4

  日期：2002.6

  Bivalent doxorubicin (DOX)-dipeptides (16a-c) were prepared and conjugated to the monoclonal antibody BR96. The dipeptides are cleaved by lysosomal proteases following internalization of the resulting immunoconjugates. Conjugate 18b demonstrated antigen-specific in vitro tumor cell killing activity (IC50 = 0.2 muM) that was equipotent to DOX with a near doubling of drug molecules/MAb. Size exclusion chromatography showed 18b to be a noncovalent dimer that was formed immediately upon conjugation. (C) 2002 Elsevier Science Ltd. All rights reserved.